Targacept Inc (TRGT.O)

TRGT.O on Nasdaq

4.08USD
16 Apr 2014
Price Change (% chg)

$0.08 (+2.00%)
Prev Close
$4.00
Open
$4.03
Day's High
$4.10
Day's Low
$3.93
Volume
122,230
Avg. Vol
201,710
52-wk High
$6.11
52-wk Low
$3.75

TRGT.O

Chart for TRGT.O

About

Targacept, Inc. is a biopharmaceutical company. The Company is engaged in the design, discovery and development of NNR Therapeutics for the treatment of diseases and disorders of the nervous system. The Company's NNR Therapeutics target neuronal nicotinic receptors (NNRs). As of December 31, 2011, the Company had multiple... (more)

Overall

Beta: 4.08
Market Cap (Mil.): $134.98
Shares Outstanding (Mil.): 33.74
Dividend: --
Yield (%): --

Financials

  TRGT.O Industry Sector
P/E (TTM): -- 32.56 32.65
EPS (TTM): -1.39 -- --
ROI: -29.83 19.75 19.01
ROE: -30.08 20.45 19.78
Search Stocks

AstraZeneca returns several compounds to Targacept

- Biotech company Targacept Inc said British drugmaker AstraZeneca would return rights to several pre-clinical compounds, sending the U.S. company's shares down 10 percent in extended trading.

10 Feb 2014

AstraZeneca returns several compounds to Targacept

Feb 10 - Biotech company Targacept Inc said British drugmaker AstraZeneca would return rights to several pre-clinical compounds, sending the U.S. company's shares down 10 percent in extended trading.

10 Feb 2014

Targacept shares plunge after schizophrenia drug dropped

- Targacept Inc shares lost nearly a third of their value before the bell on Tuesday, a day after the company said it would stop developing its experimental schizophrenia drug following disappointing trial results.

17 Dec 2013

Targacept shares plunge after schizophrenia drug dropped

Dec 17 - Targacept Inc shares lost nearly a third of their value before the bell on Tuesday, a day after the company said it would stop developing its experimental schizophrenia drug following disappointing trial results.

17 Dec 2013

BRIEF-Targacept down 31.9 percent premarket

NEW YORK, Dec 17 - Targacept Inc : * Down 31.9 percent to $4.05 in premarket; announced negative top line results from phase 2b clinical trial of schizophrenia treatment

17 Dec 2013

Competitors

  Price Change
Eisai Co., Ltd (4523.T) ¥3,958 +28.00
Pfizer Inc. (PFE.N) $30.09 +0.20
Johnson & Johnson (JNJ.N) $98.75 -0.45
Novartis AG (NOVN.VX) CHF74.35 +0.80
Merck & Co., Inc. (MRK.N) $56.26 +0.21
Roche Holding Ltd. (ROG.VX) CHF254.20 +0.90
Abbott Laboratories (ABT.N) $38.38 +0.41
Sanofi SA (SASY.PA) €74.77 +0.75
AstraZeneca plc (AZN.L) 3,758.50p +35.50
GlaxoSmithKline plc (GSK.L) 1,563.50p +16.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: Wright Reports
$75.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks